Estimating past hepatitis C infection risk from reported risk factor histories: Implications for imputing age of infection and modeling fibrosis progression

BMC Infectious Diseases

Volumn 7, Issue , 2007, Pages

  Bacchetti, Peter ^a   Tien, Phyllis C ^b   Seaberg, Eric C ^c   O'Brien, Thomas R ^d   Augenbraun, Michael H ^e   Kral, Alex H ^a   Busch, Michael P ^a   Edlin, Brian R ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG USE; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; UNCERTAINTY; URBAN AREA; AGED; BIOLOGICAL MODEL; CROSS-SECTIONAL STUDY; FIBROSIS; HEPATITIS C VIRUS; IMMUNOLOGY; INFECTION; LIVER; MALE; MIDDLE AGED; ONSET AGE; PATHOLOGY; STATISTICAL MODEL; SUBSTANCE ABUSE;

ADULT; AGE OF ONSET; AGED; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INFECTION; LIKELIHOOD FUNCTIONS; LIVER; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROBABILITY; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 39149102518     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-7-145     Document Type: Article

References (47)

1. Alter MJ Kruszon-Moran D Nainan OV McQuillan GM Gao F Moyer LA Kaslow RA Margolis HS The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 1999, 34: 556-62 10.1056/ NEJM199908193410802 10451460
2. Poynard T Ratziu V Benhamou Y Opolon P Cacoub P Bedossa P Natural History of HCV Infection Bailliere's Clinical Gastroenterology 2000, 14;211-218 10.1053/bega.1999.0071
3. Consensus Development Panel National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C: June 10-12, 2002 HIV Clin Trials 2003, 4:55-75 10.1310/86XW-Y6PX-TNE7-YM7J 12577198
4. Bell J Batey RG Farrell GC Crewe EB Cunningham AL Byth K Hepatitis C virus in intravenous drug users Med J Aust 1990, 153:274-276 2118227
5. Zeldis JB Jain S Kuramoto IK Richards C Sazama K Samuels S Holland PV Flynn N Seroepidemiology of viral infections among intravenous drug users in northern California West J Med 1992, 156:30-35 1003142 1310362
6. Thomas DL Vlahov D Solomon L Cohn S Taylor E Garfein R Nelson KE Correlates Of Hepatitis-C Virus-Infections Among Injection-Drug Users Medicine 1995, 74:212-220 10.1097/00005792-199507000-00005 7623656
7. Garfein RS Vlahov D Galai N Doherty MC Nelson KE Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses American Journal of Public Health 1996, 86:655-661 1380472 8629715
8. Lorvick J Kral AH Seal K Gee L Edlin BR Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif American Journal of Public Health 2001, 91:46-47 1446502 11189823
9. Augenbraun M Goedert JJ Thomas D Feldman J Seaberg EC French AL Robison E Nowicki M Terrault N Incident hepatitis C virus in women with human immunodeficiency virus infection Clinical Infectious Diseases 2003, 37:1357-1364 10.1086/379075 14583870
10. Koblin BA Factor SH Wu Y Vlahov D Hepatitis C virus infection among noninjecting drug users in New York City J Med Virol 2003, 70:387-390 10.1002/jmv.10407 12767001
11. Fuller CM Ompad DC Galea S Wu Y Koblin B Vlahov D Hepatitis C incidence - a comparison between injection and noninjection drug users in New York City J Urban Health 2004, 81:20-24 15047780
12. Hagan H Thiede H Des Jarlais DC Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion Epidemiology 2004, 15:543-549 10.1097/01.ede.0000135170.54913.9d 15308953
13. Howe CJ Fuller CM Ompad DC Galea S Koblin B Thomas D Vlahov D Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City Drug Alcohol Depend 2005, 79:389-95 10.1016/j.drugalcdep.2005.03.004 16102381
14. Poynard T Bedossa P Opolon P Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 1997, 349:825-32 10.1016/S0140-6736(96)07642-8 9121257
15. RoudotThoraval F Bastie A Pawlotsky JM Dhumeaux D Audigier JC Barbare JC Baudet JG Beaugrand M Berthelot P Brechot C Pol S Cattan D Bettan L Chaput JC Couzigou P Dao MT Denis J Doffoel M Drucker J Erlinger S Marcellin P Etienne JP Buffet C LaurentPuig P Filoche B Gaucher P Gauthier A Delrez R Ink O Metman E Bacq Y Michel H Larrey D Miguet JP BressonHadni S MorichauBeauchant M Opolon P Poynard T Pascal JP Payen JL Poupon R Serfaty L Sondag D Terris G Trepo C Ahmed SNS Wagner JC Zarski JP Maynard M Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French Survey of 6,664 patients Hepatology 1997, 26:485-490 10.1002/hep.510260233 9252163
16. Thomas DL Astemborski J Rai RM Anania FA Schaeffer M Galai N Nolt K Nelson KE Strathdee SA Johnson L Laeyendecker O Boitnott J Wilson LE Vlahov D The natural history of hepatitis C virus infection: Host, viral, and environmental factors JAMA 2000, 284:450-456 10.1001/ jama.284.4.450 10904508
17. Benhamou Y Di Martino V Bochet M Colombet G Thibault V Liou A Katlama C Poynard T Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy Hepatology 2001, 34:283-287 10.1053/jhep.2001.26517 11481613
18. Freeman AJ Dore GJ Law MG Thorpe M Von Overbeck J Lloyd AR Marinos G Kaldor JM Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 2001, 34:809-816 10.1053/jhep.2001.27831 11584380
19. Poynard T Ratziu V Charlotte F Goodman Z McHutchison J Albrecht J Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J Hepatology 2001, 34:730-739 10.1016/S0168-8278(00)00097-0
20. Deuffic-Burban S Poynard T Valleron AJ Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model Journal of Viral Hepatitis 2002, 9:114-122 10.1046/ j.1365-2893.2002.00340.x 11876793
21. Monto A Alonzo J Watson JJ Grunfeld C Wright TL Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol Hepatology 2002, 36:729-736 10.1053/jhep.2002.35064 12198667
22. Sypsa V Touloumi G Tassopoulos NC Ketikoglou I Vafiadi I Hatzis G Tsantoulas D Akriviadis E Delladetsima J Demonakou M Hatzakis A Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection J Viral Hepat 2004, 11(4):366-374 10.1111/j.1365-2893.2004.00517.x 15230860
23. Barkan SE Melnick SL Preston-Martin S Weber K Kalish LA Miotti P Young M Greenblatt R Sacks H Feldman J The Women's Interagency HIV Study Epidemiology 1998, 9:117-125 10.1097/00001648-199803000-00004 9504278
24. Bacon MC von Wyl V Alden C Sharp G Robison E Hessol N Gange S Barranday Y Holman S Weber K Young MA The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench Clin Diagn Lab Immunol 2005, 12:1013-1019 1235804 16148165 10.1128/ CDLI.12.9.1013-1019.2005
25. Watters JK Estilo MJ Clark GL Lorvick J Syringe and needle exchange as HIV/AIDS prevention for injection drug users JAMA 1994, 271:115-120 10.1001/jama.271.2.115 8264065
26. Kral AH Bluthenthal RN Lorvick J Gee L Bacchetti P Edlin BR Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis Lancet 2001, 357:1397-1401 10.1016/ S0140-6736(00)04562-1 11356437
27. Kral AH Lorvick J Gee L Bacchetti P Rawal B Busch M Edlin BR Trends in HIV Seroincidence among Street-Recruited Injection Drug Users in San Francisco, 1987 through 1998 Am J Epidemiol 2003, 157:915-922 10.1093/ aje/kwg070 12746244
28. Iguchi MY Bux DA Lidz V Kushner H French JF Platt JJ Interpreting HIV seroprevalence data from a street-based outreach program J Acquir Immune Defic Syndr 1994, 7:491-499 8158544
29. Nelson KE Vlahov D Solomon L Cohn S Munoz A Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md Arch Intern Med 1995, 155:1305-1311 10.1001/ archinte.155.12.1305 7778962
30. Grummer-Strawn LM Regression analysis of current-status data: An application to breast-feeding J Am Stat Assoc 1993, 88:758-765 10.2307/ 2290760 12155396
31. Shiboski SC Generalized Additive Models for Current Status Data Lifetime Data Analysis 1998, 4:29-50 10.1023/A:1009652024999 9567054
32. Martinussen BT Scheike TH Efficient estimation in additive hazards regression with current status data Biometrika 2002, 89:649-658 10.1093/ biomet/89.3.649
33. Wong K-F Tsai W-Y Kuhn L Estimating HIV hazard rates from cross-sectional HIV prevalence data Statist Med 2006, 25:2441-2449 10.1002/sim.2371
34. Cox DR Regression models and life-tables (with discussion) J Royal Statist Soc, Ser B 1972, 34:187-220
35. D'Agostino RB Lee ML Belanger AJ Cupples LA Anderson K Kannel WB Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study Statist Med 1990, 9:1501-1515 10.1002/sim.4780091214
36. Buxton MB Vlahov D Strathdee SA Des Jarlais DC Morse EV Ouellet L Kerndt P Garfein RS Association between injection practices and duration of injection among recently initiated injection drug users Drug and Alcohol Dependence 2004, 75:177-183 10.1016/j.drugalcdep.2004.01.014
37. Spada E Mele A Ciccozzi M Tosti ME Bianco E Szklo A Ragni P Gallo G Balocchini E Sangalli M Lopalco PL Moiraghi A Stroffolini T Changing epidemiology of parenterally transmitted viral hepatitis: Results from the hepatitis surveillance system in Italy Digest Liver Dis 2001, 33:778-784 10.1016/S1590-8658(01)80695-2
38. van de Laar TJW Langendam MW Bruisten SM Welp EAE Verhaest I van Ameijden EJC Coutinho RA Prins M Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands Journal of Medical Virology 2005, 77:509-518 10.1002/ jmv.20486 16254983
39. Muga R Sanvisens A Bolao F Tor J Santesmases J Pujol R Tural C Langohr K Rey-Joly C Munoz A Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001 Drug and Alcohol Dependence 2006, 82:S29-S33 10.1016/S0376-8716(06)80005-0
40. Tseng FC O'Brien TR Zhang M Kral AH Ortiz-Conde BA Lorvick J Busch MP Edlin BR Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000 Hepatology 2007, 46:666-671 10.1002/hep.21765 17657818
41. Schafer JL Multiple Imputation: A Primer Statistical Methods in Medical Research 1999, 8:3-15 10.1191/096228099671525676 10347857
42. Bedossa P Poynard T An algorithm for the grading of activity in chronic hepatitis C Hepatology 1996, 24:289-293 10.1002/hep.510240201 8690394
43. Bacchetti P Age and variant Creutzfeldt-Jakob disease Emerging Infectious Diseases 2003, 9:1611-1612 14720404
44. Tortu S Neaigus A McMahon J Hagen D Hepatitis C among noninjecting drug users: A report Substance Use & Misuse 2001, 36:523-534 10.1081/ JA-100102640 11346280
45. Busch MP Glynn SA Stramer SL Orland J Murphy EL Wright DJ Kleinman S Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors Transfusion 2006, 46:469-475 10.1111/ j.1537-2995.2006.00745.x 16533292
46. Chamie G Bonacini M Bangsberg DR Stapleton JT Hall C Overton ET Scherzer R Tien PC Factors associated with seronegative chronic hepatitis C virus infection in HIV-infection Clinical Infectious Diseases 2007, 44:577-583 10.1086/511038 17243063
47. Mizukoshi E Eisenbach C Edlin B Weiler C Carrington M O'Brien T Rehermann B HCV-specific cellular immune responses in subjects who are antiHCV-negative, HCV RNA-negative despite longterm (> 15 years) injection drug use Hepatology 2003, 38:210A 10.1016/S0270-9139(03)80154-4